Zacks.com users have recently been watching Boston Scientific (BSX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
BSX beats Q2 estimates, raises full-year outlook as Cardiovascular sales surge and global revenues climb 22.8%.
29 Oct 2025 (In 2 months) Date | | 0.71 Cons. EPS | - EPS |
21 Oct 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
23 Jul 2025 Date | | 0.73 Cons. EPS | - EPS |
22 Jul 2025 Date | | - Cons. EPS | - EPS |
23 Apr 2025 Date | | - Cons. EPS | - EPS |
29 Oct 2025 (In 2 months) Date | | 0.71 Cons. EPS | - EPS |
21 Oct 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
23 Jul 2025 Date | | 0.73 Cons. EPS | - EPS |
22 Jul 2025 Date | | - Cons. EPS | - EPS |
23 Apr 2025 Date | | - Cons. EPS | - EPS |
Medical - Devices Industry | Healthcare Sector | Michael F. Mahoney CEO | XDUS Exchange | US1011371077 ISIN |
US Country | 53,000 Employees | - Last Dividend | 6 Nov 2003 Last Split | 18 May 1992 IPO Date |
Boston Scientific Corporation is a global developer, manufacturer, and marketer of medical devices used in a variety of interventional medical specialties. Having begun its operations in 1979, the company has grown to serve a diverse range of medical needs through its two primary segments: MedSurg and Cardiovascular. With its headquarters in Marlborough, Massachusetts, Boston Scientific is committed to improving patient health by providing cutting-edge solutions that address complex medical conditions and enhance the quality of life for patients worldwide.